NICE Draft Guidance Recommends Secukinumab for Severe Plaque Psoriasis

Pavankumar Kamat

September 07, 2021

The National Institute for Health and Care Excellence (NICE) has recommended secukinumab (Cosentyx, Novartis) as a treatment option for severe plaque psoriasis in young people in a draft guidance published recently.

Secukinumab is recommended for the treatment of children aged 6-17 years with plaque psoriasis if the following conditions are fulfilled:

  • Total Psoriasis Area and Severity Index (PASI) of ≥10.

  • Inadequate response, intolerance or contraindication to other systemic therapies, including ciclosporin, methotrexate and phototherapy.

Secukinumab is administered subcutaneously based on the body weight as per the summary of product characteristics.

Treatment with secukinumab should be stopped if an adequate therapeutic response (75% reduction in the PASI score from treatment initiation) is not achieved after 12 weeks. Appropriate clinical adjustments should be made after accounting for the possible influence of skin colour on the PASI score.

Clinical trial evidence showed secukinumab to be more effective than etanercept. An indirect comparison of secukinumab and ustekinumab showed comparable effectiveness. The effectiveness of secukinumab versus adalimumab remains uncertain due to limited evidence, but adalimumab is believed to be similarly effective to ustekinumab.

The cost-effectiveness of secukinumab is comparable to or lower than that of adalimumab, etanercept and ustekinumab.

The drug is to be used only when provided by the company in agreement with the commercial arrangement. The recommendations should not affect patients whose treatment with the drugs was started before publication of the final guidance, which is expected in October 2021.

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.